Peplin completes Neosil buy

By Staff Writers
Monday, 20 October, 2008

Peplin has completed its US$6.7 million purchase of private dermatology company Neosil.

The Brisbane biotech issued shares iin common stock in exchange for all equity interests in Neosil, which is developing a topical hair growth product and a broad-spectrum topical anti-microbial agent for acne.

Peplin shareholders have also approved a private placement of stock to raise US$24 million to help fund its Phase III trial of PEP005, a topical gel for sun spots.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd